Ultragenyx Pharmaceutical | RARE - Debt



Ultragenyx Pharmaceutical reported $36.3M in Debt for its fiscal quarter ending in June of 2025.


Debt Change Date
Acadia Pharmaceuticals USD 56.29M 56.29M Jun/2025
Agios Pharmaceuticals USD 48.76M 48.76M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 271.5M Jun/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Insmed USD 564.1M 567.29M Jun/2025
Ionis Pharmaceuticals USD 1.42B 169.27M Jun/2025
Kyowa Hakko Kirin JPY 0 28.75B Mar/2025
MacroGenics USD 37.25M 37.25M Jun/2025
Moderna USD 741M 4M Jun/2025
Neurocrine Biosciences USD 439.1M 8.4M Jun/2025
PTC Therapeutics USD 286.01M 2.12B Jun/2025
Regeneron Pharmaceuticals USD 2.71B 300K Jun/2025
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
Ultragenyx Pharmaceutical USD 36.3M 1.98M Jun/2025
Vertex Pharmaceuticals USD 1.53B 121.7M Jun/2025